Dual HER2-targeted approaches in HER2-positive breast cancer

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 371-383

  Ahn, Eugene R ^a   Vogel, Charles L ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Breast cancer; HER2; Lapatinib; Pertuzumab; Trastuzumab

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; LAPATINIB; LETROZOLE; NERATINIB; PACLITAXEL; PERIFOSINE; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE; TEMSIROLIMUS; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; BREAST SURGERY; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIARRHEA; DIPLOPIA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIVER DISEASE; MEDICAL SOCIETY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SYMPOSIUM; SYSTOLIC DYSFUNCTION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 84856223809     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1781-y     Document Type: Review

References (99)

1. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 1:CAS:528:DyaL2sXhtVSht7s%3D 10.1126/science.3798106 (Pubitemid 17231334)
2. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137 11252954 1:CAS:528:DC%2BD3MXivVWnt7k%3D 10.1038/35052073 (Pubitemid 33674041)
3. NE Hynes 1993 Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy Semin Cancer Biol 4 19 26 8095411 1:CAS:528:DyaK3sXlslyns7s%3D
4. S Menard E Tagliabue M Campiglio SM Pupa 2000 Role of HER2 gene overexpression in breast carcinoma J Cell Physiol 182 150 162 10623878 1:CAS:528:DC%2BD3cXjtVGqsA%3D%3D 10.1002/(SICI)1097-4652(200002)182:2<150:: AID-JCP3>3.0.CO;2-E (Pubitemid 30022667)
5. JS Ross EA Slodkowska WF Symmans L Pusztai PM Ravdin GN Hortobagyi 2009 The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine The Oncologist 14 320 368 19346299 1:CAS:528:DC%2BD1MXlvFOhtLw%3D 10.1634/theoncologist.2008-0230
6. J Baselga 2010 Treatment of HER2-overexpressing breast cancer Ann Oncol 21 Suppl 7 vii36 vii40 20943641 10.1093/annonc/mdq421
7. D Gajria S Chandarlapaty 2011 HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies Expert Rev Anticancer Ther 11 263 275 21342044 1:CAS:528:DC%2BC3MXisVWmsbk%3D 10.1586/era.10.226
8. JT Garrett CL Arteaga 2011 Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications Cancer Biol Ther 11 793 800 21307659 10.4161/cbt.11.9.15045
9. KL Jones AU Buzdar 2009 Evolving novel anti-HER2 strategies Lancet Oncol 10 1179 1187 19959074 1:CAS:528:DC%2BD1MXhsV2lurrJ 10.1016/S1470-2045(09)70315-8
10. NL Spector KL Blackwell 2009 Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 27 5838 5847 19884552 1:CAS:528:DC%2BC3cXhtVWitro%3D 10.1200/JCO.2009.22.1507
11. E Tzahar H Waterman X Chen G Levkowitz D Karunagaran S Lavi BJ Ratzkin Y Yarden 1996 A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Mol Cell Biol 16 5276 5287 8816440 1:CAS:528:DyaK28XlvFamt70%3D (Pubitemid 26315047)
12. D Graus-Porta RR Beerli JM Daly NE Hynes 1997 ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J 16 1647 1655 9130710 1:CAS:528:DyaK2sXislKltLo%3D 10.1093/emboj/16.7.1647 (Pubitemid 27151960)
13. R Pinkas-Kramarski L Soussan H Waterman G Levkowitz I Alroy L Klapper S Lavi R Seger BJ Ratzkin M Sela Y Yarden 1996 Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions EMBO J 15 2452 2467 8665853 1:CAS:528:DyaK28XjsVGjurY%3D (Pubitemid 26151185)
14. J Baselga SM Swain 2009 Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat Rev Cancer 9 463 475 19536107 1:CAS:528: DC%2BD1MXnsVagtbs%3D 10.1038/nrc2656
15. HH Kim SL Sierke JG Koland 1994 Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product J Biol Chem 269 24747 24755 7929151 1:CAS:528:DyaK2cXlslWgsbc%3D
16. MA Olayioye RM Neve HA Lane NE Hynes 2000 The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J 19 3159 3167 10880430 1:CAS:528:DC%2BD3cXlt1ajtLY%3D 10.1093/emboj/19.13.3159 (Pubitemid 30428195)
17. EK Rowinsky 2004 The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors Annu Rev Med 55 433 457 14746530 1:CAS:528: DC%2BD2cXitVWru74%3D 10.1146/annurev.med.55.091902.104433 (Pubitemid 38316736)
18. SP Soltoff KL Carraway III SA Prigent WG Gullick LC Cantley 1994 ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor Mol Cell Biol 14 3550 3558 7515147 1:CAS:528:DyaK2cXktVWqsL4%3D (Pubitemid 24160762)
19. PM Guy JV Platko LC Cantley RA Cerione KL Carraway III 1994 Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity Proc Natl Acad Sci USA 91 8132 8136 8058768 1:CAS:528:DyaK2cXlsV2qurg%3D 10.1073/pnas.91.17.8132 (Pubitemid 24253900)
20. T Holbro RR Beerli F Maurer M Koziczak CF Barbas III NE Hynes 2003 The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Proc Natl Acad Sci USA 100 8933 8938 12853564 1:CAS:528:DC%2BD3sXlvVyitbY%3D 10.1073/pnas.1537685100 (Pubitemid 36899201)
21. AC Hsieh MM Moasser 2007 Targeting HER proteins in cancer therapy and the role of the non-target HER3 Br J Cancer 97 453 457 17667926 1:CAS:528:DC%2BD2sXptVWju7g%3D 10.1038/sj.bjc.6603910 (Pubitemid 47258458)
22. JA Menendez R Lupu 2007 Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3 J Clin Oncol 25 2496 2498 17557968 1:CAS:528:DC%2BD2sXns1Kmtbk%3D 10.1200/JCO.2007.11.0395 (Pubitemid 46999231)
23. MA Cobleigh CL Vogel D Tripathy NJ Robert S Scholl L Fehrenbacher JM Wolter V Paton S Shak G Lieberman DJ Slamon 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 10561337 1:CAS:528:DyaK1MXmtlWrurk%3D (Pubitemid 29415219)
24. G von Minckwitz BA du M Schmidt N Maass T Cufer FE de Jongh E Maartense C Zielinski M Kaufmann W Bauer KH Baumann MR Clemens R Duerr C Uleer M Andersson RC Stein V Nekljudova S Loibl 2009 Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 1999 2006 10.1200/JCO.2008.19.6618
25. S Dawood K Broglio AU Buzdar GN Hortobagyi SH Giordano 2010 Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 92 98 19933921 1:CAS:528: DC%2BC3cXhtF2rsr0%3D 10.1200/JCO.2008.19.9844
26. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Anton A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 15911866 1:CAS:528: DC%2BD2MXms12gs70%3D 10.1200/JCO.2005.04.173 (Pubitemid 46207001)
27. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 (Pubitemid 32222155)
28. L Gianni W Eiermann V Semiglazov A Manikhas A Lluch S Tjulandin M Zambetti F Vazquez M Byakhow M Lichinitser MA Climent E Ciruelos B Ojeda M Mansutti A Bozhok R Baronio A Feyereislova C Barton P Valagussa J Baselga 2010 Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 377 384 20113825 1:CAS:528:DC%2BC3cXht12ltLk%3D 10.1016/S0140-6736(09)61964-4
29. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Láng U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Rüschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 1:CAS:528:DC%2BD2MXhtFansr3L 10.1056/NEJMoa052306 (Pubitemid 41464705)
30. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 1:CAS:528:DC%2BD2MXhtFansr3F 10.1056/NEJMoa052122 (Pubitemid 41464706)
31. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, Chan A, Mackey J, Liu M, Pinter T, Valero V, Falkson C, Fornander T, Shiftan T, Olsen S, Buyse M, Kiskartalyi T, Landreau V, Wilson V, Press M, Crown J, on behalf of BCIRG006 investigators (2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study (Abstract no. 62). Cancer Res 69(24 Suppl):62
32. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga M Kaufmann D Cameron R Bell J Bergh R Coleman A Wardley N Harbeck RI Lopez P Mallmann K Gelmon N Wilcken E Wist RP Sanchez MJ Piccart-Gebhart 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36 17208639 1:CAS:528:DC%2BD2sXit12itg%3D%3D 10.1016/S0140- 6736(07)60028-2 (Pubitemid 46039831)
33. M Untch M Rezai S Loibl PA Fasching J Huober H Tesch I Bauerfeind J Hilfrich H Eidtmann B Gerber C Hanusch T Kuhn BA du JU Blohmer C Thomssen CS Dan C Jackisch M Kaufmann K Mehta MG von 2010 Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J Clin Oncol 28 2024 2031 20308670 1:CAS:528:DC%2BC3cXmtlSksrg%3D 10.1200/JCO.2009.23.8451
34. M Barok J Isola Z Palyi-Krekk P Nagy I Juhasz G Vereb P Kauraniemi A Kapanen M Tanner G Vereb J Szollosi 2007 Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance Mol Cancer Ther 6 2065 2072 17620435 1:CAS:528:DC%2BD2sXnsV2js70%3D 10.1158/1535-7163.MCT-06-0766 (Pubitemid 47052497)
35. R Ghosh A Narasanna SE Wang S Liu A Chakrabarty JM Balko AM Gonzalez-Angulo GB Mills E Penuel J Winslow J Sperinde R Dua S Pidaparthi A Mukherjee K Leitzel WJ Kostler A Lipton M Bates CL Arteaga 2011 Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers Cancer Res 71 1871 1882 21324925 1:CAS:528:DC%2BC3MXisFCnsLk%3D 10.1158/0008-5472.CAN- 10-1872
36. HS Cho K Mason KX Ramyar AM Stanley SB Gabelli DW Denney Jr DJ Leahy 2003 Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 756 760 12610629 1:CAS:528:DC%2BD3sXhsV2rtrw%3D 10.1038/nature01392 (Pubitemid 36227628)
37. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 443 446 10742152 1:CAS:528:DC%2BD3cXisVOru7Y%3D 10.1038/74704 (Pubitemid 30208162)
38. BM Fendly M Winget RM Hudziak MT Lipari MA Napier A Ullrich 1990 Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product Cancer Res 50 1550 1558 1689212 1:CAS:528:DyaK3cXhslKltrw%3D (Pubitemid 20090470)
39. MX Sliwkowski JA Lofgren GD Lewis TE Hotaling BM Fendly JA Fox 1999 Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin Oncol 26 4 Suppl 12 60 70 10482195 1:CAS:528: DyaK1MXmt1SisbY%3D (Pubitemid 29411434)
40. DB Agus RW Akita WD Fox GD Lewis B Higgins PI Pisacane JA Lofgren C Tindell DP Evans K Maiese HI Scher MX Sliwkowski 2002 Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 127 137 12204533 1:CAS:528:DC%2BD38XmslSksL4%3D 10.1016/S1535-6108(02)00097-1 (Pubitemid 41039113)
41. P Nagy E Friedlander M Tanner AI Kapanen KL Carraway J Isola TM Jovin 2005 Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res 65 473 482 15695389 1:CAS:528:DC%2BD2MXns1KqsA%3D%3D
42. J Codony-Servat J Albanell JC Lopez-Talavera J Arribas J Baselga 1999 Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells Cancer Res 59 1196 1201 10096547 1:CAS:528:DyaK1MXhvFeht7c%3D (Pubitemid 29136246)
43. M Scaltriti F Rojo A Ocana J Anido M Guzman J Cortes S Di Cosimo X Matias-Guiu S Ramon y Cajal J Arribas J Baselga 2007 Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer J Natl Cancer Inst 99 628 638 17440164 1:CAS:528: DC%2BD2sXlvVSktr4%3D 10.1093/jnci/djk134 (Pubitemid 47073544)
44. K Berns HM Horlings BT Hennessy M Madiredjo EM Hijmans K Beelen SC Linn AM Gonzalez-Angulo K Stemke-Hale M Hauptmann RL Beijersbergen GB Mills MJ van de Vijver R Bernards 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395 402 17936563 1:CAS:528:DC%2BD2sXht1ais7zL 10.1016/j.ccr.2007.08.030 (Pubitemid 47539306)
45. Y Nagata KH Lan X Zhou M Tan FJ Esteva AA Sahin KS Klos P Li BP Monia NT Nguyen GN Hortobagyi MC Hung D Yu 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 15324695 1:CAS:528:DC%2BD2cXns1arsr8%3D 10.1016/j.ccr.2004.06.022 (Pubitemid 39485684)
46. NV Sergina M Rausch D Wang J Blair B Hann KM Shokat MM Moasser 2007 Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445 437 441 17206155 1:CAS:528:DC%2BD2sXos12msA%3D%3D 10.1038/nature05474 (Pubitemid 46160912)
47. A Ocana JJ Cruz A Pandiella 2006 Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance Am J Clin Oncol 29 90 95 16462510 1:CAS:528:DC%2BD28Xis1antbs%3D 10.1097/01.coc.0000190274.00570.0a (Pubitemid 44356722)
48. GE Konecny MD Pegram N Venkatesan R Finn G Yang M Rahmeh M Untch DW Rusnak G Spehar RJ Mullin BR Keith TM Gilmer M Berger KC Podratz DJ Slamon 2006 Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 1630 1639 16452222 1:CAS:528:DC%2BD28XpsVemsg%3D%3D 10.1158/0008-5472.CAN-05- 1182 (Pubitemid 43259947)
49. Tykerb [package insert] (2011) Available at http://us.gsk.com/products/ assets/us-tykerb.pdf. Accessed 3 June 2011
50. CE Geyer J Forster D Lindquist S Chan CG Romieu T Pienkowski A Jagiello-Gruszfeld J Crown A Chan B Kaufman D Skarlos M Campone N Davidson M Berger C Oliva SD Rubin S Stein D Cameron 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 17192538 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 10.1056/NEJMoa064320 (Pubitemid 46021510)
51. KL Blackwell HJ Burstein AM Storniolo H Rugo G Sledge M Koehler C Ellis M Casey S Vukelja J Bischoff J Baselga J O'Shaughnessy 2010 Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 1124 1130 20124187 1:CAS:528:DC%2BC3cXktF2ltLo%3D 10.1200/JCO.2008.21.4437
52. S Johnston J Pippen Jr X Pivot M Lichinitser S Sadeghi V Dieras HL Gomez G Romieu A Manikhas MJ Kennedy MF Press J Maltzman A Florance L O'Rourke C Oliva S Stein M Pegram 2009 Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 5538 5546 19786658 1:CAS:528: DC%2BC3cXhtVWit7w%3D 10.1200/JCO.2009.23.3734
53. Kaklamani VG, Siziopikou K, Scholtens D, Lacouture M, Gordon J, Uthe R, Meservey C, Hansen N, Khan SA, Jeruss JS, Bethke K, Cianfrocca M, Rosen S, Von RJ, Wayne J, Parimi V, Jovanovic B, Gradishar W (2011) Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat [Epub ahead of print]
54. SD Costa C Jackisch C Thomssen 2010 Future roles of lapatinib in ErbB2-positive breast cancer: adjuvant and neoadjuvant trials Breast Care (Basel) 5 22 24 10.1159/000285778
55. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching P., Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kuhn T, Nekljudova V, von Minckwitz G (2010) Lapatinib vs trastuzumab in combination With neoadjuvant anthracycline-taxane- based chemotherapy: primary efficacy endpoint analysis of the GeparQuinto study (Abstract no. S3-1). Presented at the 33rd annual San Antonio breast cancer symposium, San Antonio, 8-12 Dec 2010 http://www.abstracts2view.com/sabcs10/ view.php?nu=SABCS10L-240&terms=. Accessed 3 June 2011
56. IF Faneyte JG Schrama JL Peterse PL Remijnse S Rodenhuis MJ van de Vijver 2003 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 406 412 12569384 1:STN:280: DC%2BD3s%2FlvVChtA%3D%3D 10.1038/sj.bjc.6600749 (Pubitemid 36308152)
57. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra RL Theriault G Singh SM Binkley N Sneige TA Buchholz MI Ross MD McNeese AU Buzdar GN Hortobagyi SE Singletary 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 10080586 1:CAS:528: DyaK1MXht1Wmur4%3D (Pubitemid 29075229)
58. C Shimizu N Masuda K Yoshimura H Tsuda M Mano M Ando K Tamura Y Fujiwara 2009 Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer Jpn J Clin Oncol 39 484 490 19477897 10.1093/jjco/hyp052
59. KL Blackwell HJ Burstein GW Sledge S Stein C Ellis M Casey J Baselga J O'Shaughnessy 2009 Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy [abstract] Cancer Res 69 24 Suppl 61 10.1158/0008-5472.SABCS-09-61
60. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H. Dinh P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M, on behalf of the NeoALTTO Study Team (2010) First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer (Abstract no. S3-3). Presented at the 33rd annual San Antonio breast cancer symposium, San Antonio, 8-12 Dec 2010. http://www.abstracts2view.com/ sabcs10/view.php?nu=SABCS10L-291&terms=. Accessed 3 June 2011
61. J O'Shaughnessy KL Blackwell H Burstein AM Storniolo G Sledge J Baselga M Koehler S Laabs A Florance D Roychowdhury 2008 A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract] J Clin Oncol 26 15S 1015
62. V Guarneri A Frassoldati A Bottini DG Generali K Cagossi F Artioli G Bisagni C Boni A Ravaioli D Amadori A Musolino L Cavanna M Untch L Orlando G Giardina F Piacentini E Tagliafico M Bagnalasta R D'Amico PF Conte 2011 Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive cancer (CHER-LOB trial) [abstract] J Clin Oncol 29 15S 507
63. FA Holmes YM Nagarwala VA Espina LA Liotta MA Danso RI Gallagher K McIntyre CRC Osborne JM Mahoney AM Florance TC Anderson J O'Shaughnessy 2011 Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy [abstract] J Clin Oncol 29 15S 506
64. JCN Chang IA Mayer A Forero-Torres R Nanda MP Goetz AA Rodriguez AC Pavlick T Wang SG Hilsenbeck C Gutierrez R Schiff CK Osborne MF Rimawi 2011 TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer [abstract] J Clin Oncol 29 15 505
65. F Andre M Campone R O'Regan C Manlius C Massacesi T Sahmoud P Mukhopadhyay JC Soria M Naughton SA Hurvitz 2010 Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab J Clin Oncol 28 5110 5115 20975068 1:CAS:528:DC%2BC3MXltlKnsA%3D%3D 10.1200/JCO.2009.27.8549
66. HJ Burstein Y Sun LY Dirix Z Jiang R Paridaens AR Tan A Awada A Ranade S Jiao G Schwartz R Abbas C Powell K Turnbull J Vermette C Zacharchuk R Badwe 2010 Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer J Clin Oncol 28 1301 1307 20142587 1:CAS:528:DC%2BC3cXksFSqtbs%3D 10.1200/JCO.2009.25.8707
67. S Chan ME Scheulen S Johnston K Mross M Piccart D Hess N Bouxin N Azli For the CESAR/European CCI-779 Breast Group 2003 Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic beast cancer failing prior anthracycline and/or taxane regimens [abstract] Proc Am Soc Clin Oncol 22 774
68. G Jerusalem A Fasolo V Dieras F Cardoso J Bergh L Vittori Y Zhang C Massacesi T Sahmoud L Gianni 2011 Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer Breast Cancer Res Treat 125 447 455 21107682 1:CAS:528:DC%2BC3cXhsFCqt7rO 10.1007/s10549-010-1260- x
69. V Serra B Markman M Scaltriti PJ Eichhorn V Valero M Guzman ML Botero E Llonch F Atzori CS Di M Maira C Garcia-Echeverria JL Parra J Arribas J Baselga 2008 NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 8022 8030 18829560 1:CAS:528:DC%2BD1cXhtF2msLrK 10.1158/0008-5472.CAN-08-1385
70. L Van Ummersen K Binger J Volkman R Marnocha K Tutsch J Kolesar R Arzoomanian D Alberti G Wilding 2004 A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer Clin Cancer Res 10 7450 7456 15569974 10.1158/1078-0432.CCR-03-0406 (Pubitemid 39557506)
71. J Baselga KA Gelmon S Verma A Wardley P Conte D Miles G Bianchi J Cortes VA McNally GA Ross P Fumoleau L Gianni 2010 Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 1138 1144 20124182 1:CAS:528:DC%2BC3cXktF2ltLg%3D 10.1200/JCO.2009.24. 2024
72. ClinicalTrials.gov (2011) A study of MM-111 in combination with (herceptin) trastuzumab in patients with advanced Her2 positive breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT01097460. Accessed 9 June 2011
73. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch-Hernandez A, Semiglazov V, Szado T, Ross G (2010) Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere') (Abstract no. S3-2). Presented at the 33rd annual San Antonio breast cancer symposium, San Antonio, 8-12 Dec 2010. http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L-1000&terms=. Accessed 3 June 2011
74. JB Hughes C Berger MS Rodland M Hasmann E Stang IH Madshus 2009 Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization Mol Cancer Ther 8 1885 1892 19584234 1:CAS:528:DC%2BD1MXosVymsL4%3D 10.1158/1535-7163.MCT-09-0291
75. W Scheuer T Friess H Burtscher B Bossenmaier J Endl M Hasmann 2009 Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models Cancer Res 69 9330 9336 19934333 1:CAS:528:DC%2BD1MXhsFGrtbnM 10.1158/0008-5472.CAN-08-4597
76. J Baselga 2011 Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer Oncologist 16 Suppl 1 12 19 21278436 10.1634/theoncologist.2011- S1-12
77. KS Saini MJ Piccart-Gebhart 2010 Dual targeting of the PI3K and MAPK pathways in breast cancer APJOH 2 13 15
78. DB Agus MS Gordon C Taylor RB Natale B Karlan DS Mendelson MF Press DE Allison MX Sliwkowski G Lieberman SM Kelsey G Fyfe 2005 Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer J Clin Oncol 23 2534 2543 15699478 1:CAS:528:DC%2BD2MXjvVyktLk%3D 10.1200/JCO.2005.03.184 (Pubitemid 47050843)
79. J Baselga 2002 A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization Cancer Cell 2 93 95 12204526 1:CAS:528:DC%2BD38XmslSks78%3D 10.1016/S1535-6108(02)00098-3 (Pubitemid 41043172)
80. A Citri KB Skaria Y Yarden 2003 The deaf and the dumb: the biology of ErbB-2 and ErbB-3 Exp Cell Res 284 54 65 12648465 1:CAS:528:DC%2BD3sXitVyltrg%3D 10.1016/S0014-4827(02)00101-5 (Pubitemid 36342255)
81. MC Franklin KD Carey FF Vajdos DJ Leahy AM de Vos MX Sliwkowski 2004 Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 5 317 328 15093539 1:CAS:528:DC%2BD2cXjvVaqtLc%3D 10.1016/S1535-6108(04)00083-2 (Pubitemid 38482068)
82. R Nahta MC Hung FJ Esteva 2004 The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res 64 2343 2346 15059883 1:CAS:528:DC%2BD2cXis1yjt7k%3D 10.1158/0008-5472.CAN-03-3856 (Pubitemid 38523885)
83. G Brockhoff B Heckel E Schmidt-Bruecken M Plander F Hofstaedter A Vollmann S Diermeier 2007 Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation Cell Prolif 40 488 507 17635517 1:CAS:528:DC%2BD2sXhtVSksLnF 10.1111/j.1365-2184.2007.00449.x (Pubitemid 47063288)
84. J Cortes J Baselga T Petrella K Gelmon P Fumoleau S Verma X Pivot G Ross T Szado L Gianni 2009 Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2- positive breast cancer [abstract] J Clin Oncol 27 15S 1022
85. JN Rich BK Rasheed H Yan 2004 EGFR mutations and sensitivity to gefitinib N Engl J Med 351 1260 1261 15376352 1:CAS:528:DC%2BD2cXnslSjtrw%3D 10.1056/NEJM200409163511221 (Pubitemid 39296317)
86. CC Portera JM Walshe DR Rosing N Denduluri AW Berman U Vatas M Velarde CK Chow SM Steinberg D Nguyen SX Yang SM Swain 2008 Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer Clin Cancer Res 14 2710 2716 18451236 1:CAS:528:DC%2BD1cXlsV2qtLc%3D 10.1158/1078-0432.CCR- 07-4636
87. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J (2011) Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol [Epub ahead of print]
88. ClinicalTrials.gov (2011) ALTTO (Adjuvant lapatinib and/or trastuzumab treatment optimisation) study; BIG 2-06/N063D. http://www.clinicaltrials.gov/ ct2/show/NCT00490139. Accessed 9 June 2011
89. ClinicalTrials.gov (2011) A study of AC followed by a combination of paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with operable HER2 positive invasive breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT00486668. Accessed 9 June 2011
90. ClinicalTrials.gov (2011) Docetaxel, carboplatin, and trastuzumab and/or lapatinib in treating women with stage I, stage II, or stage III breast cancer that can be removed by surgery. http://www.clinicaltrials.gov/ct2/show/ NCT00769470. Accessed 9 June 2011
91. J Baselga SM Swain 2010 CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer Clin Breast Cancer 10 489 491 21147694 10.3816/CBC.2010.n.065
92. ClinicalTrials.gov (2011) A study of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer (PHEREXA). http://www.clinicaltrials.gov/ct2/show/ NCT01026142. Accessed 3 June 2011
93. ClinicalTrials.gov (2011) A study of pertuzumab in combination with Herceptin and chemotherapy in patients with HER2-positive breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT00976989. Accessed 3 June 2011
94. ClinicalTrials.gov (2011) A study of trastuzumab-DM1 plus pertuzumab versus trastuzumab [Herceptin] plus a taxane in patients with metastatic breast cancer (MARIANNE). http://www.clinicaltrials.gov/ct2/show/NCT01120184. Accessed 3 June 2011
95. HA Burris III HS Rugo SJ Vukelja CL Vogel RA Borson S Limentani E Tan-Chiu IE Krop RA Michaelson S Girish L Amler M Zheng YW Chu B Klencke JA O'Shaughnessy 2011 Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy J Clin Oncol 29 398 405 21172893 1:CAS:528:DC%2BC3MXivFWmsrc%3D 10.1200/JCO.2010.29.5865
96. CT Fields LM Crocker MX Sliwkowski GD Lewis Phillips 2010 Dual targeting of HER2: enhanced anti-tumor efficacy of trastuzumab-DM1 combined with pertuzumab Proc Am Assoc Cancer Res 51 5607
97. A Maloney P Workman 2002 HSP90 as a new therapeutic target for cancer therapy: the story unfolds Expert Opin Biol Ther 2 3 24 11772336 1:CAS:528:DC%2BD38XnsVaksw%3D%3D 10.1517/14712598.2.1.3 (Pubitemid 34462457)
98. K Sakai H Yokote K Murakami-Murofushi T Tamura N Saijo K Nishio 2007 Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway Cancer Sci 98 1498 1503 17627612 1:CAS:528:DC%2BD2sXhtVaksrjI 10.1111/j.1349-7006.2007.00553.x (Pubitemid 47241776)
99. DB Solit G Chiosis 2008 Development and application of Hsp90 inhibitors Drug Discov Today 13 38 43 18190862 1:CAS:528:DC%2BD1cXlsVWhug%3D%3D 10.1016/j.drudis.2007.10.007